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Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood. The treatment of JIA
has been revolutionized in the last decade by the use of
novel biologic agents that have much improved patients’
outcomes.
Aim
To evaluate the efficacy and safety profile of long-term
administration of etanercept (ETN) to JIA patients, in
combination or not with DMARDs, such as methotrexate.
Methods
We enrolled 25 patients affected by JIA fulfilling the
ILAR criteria and undergoing ETN treatment from 6/
1999 to 12/2010, in combination with methotrexate 12
of them. Medical charts were reviewed for physical and
laboratory findings. All patients’ clinical status was mon-
itored for functional consequences of JIA by the Stein-
brocker’s revised criteria. It was confirmed that all
patients had already received BCG vaccination at onset.
The mean duration of disease prior to ETN treatment
was 10 years while the mean duration of ETN adminis-
tration was 51 months (range 26-74). All patients were
closely monitored for adverse events. ETN was discon-
tinued in 7 patients whose follow-up for a mean period
of 15.7 months (range 26-74) was free of relapse.
Results
Response to ETN was evident in 24 patients, of whom
18 had a very early amelioration of clinical signs and
symptoms in the first month. Physical disability was
improving throughout the follow-up. Ten patients met
the criteria of clinical remission on medication. After
withdrawal of ETN the disease remained inactive until
now in 7 patients. With regard to safety concerns, no
adverse events are to be reported.
Concusion
Biologic therapy with ETN in JIA seems to be efficient
and safe
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